Source: Annual Congress 2004 - Mechanisms in allergic diseases
Disease area: Airway diseases, Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Bufe, E. Grage-Griebenow, K. Reinitz-Rademacher, H. Kalhoff, S. Loeseke, M. Kauth, T. Holland-Letz, K. Gehlhar (Bochum, Dortmund, Germany). Supression of typ-1 interferon (IFN-a) response in children with allergic asthma is associated with severity of the disease; a prospective cohort study. Eur Respir J 2004; 24: Suppl. 48, 1049

Member's Comments

No comment yet.

Related content which might interest you: Omalizumab in severe allergic asthma associated with COPD: a multicentric cohort study Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 ‘Real-life‘ persistence beyond the first year of omalizumab treatment in patients with severe allergic asthma: The R-Pixel study Source: Annual Congress 2011 - Asthma management and response Year: 2011 The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma Source: Eur Respir J 2003; 22: 470-477 Year: 2003 A randomized double-blind study of specific immunotherapy (SIT) in patients with seasonal allergic rhinitis: effects on clinical and inflammatory markers Source: Eur Respir J 2001; 18: Suppl. 33, 482s Year: 2001 Associations of serum cytokine levels with asthma, wheeze and allergic rhinitis symptoms in 5-years old children: a population-based study Source: Virtual Congress 2020 – Novel mechanisms and management of paediatric asthma Year: 2020 Effectiveness of omalizumab in Canadian patients with allergic asthma: A retrospective study. Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study Source: International Congress 2017 – Monitoring asthma control Year: 2017 Response to benralizumab in severe eosinophilic asthma after intermediate-to-poor response to mepolizumab : a retrospective study. Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: A retrospective observational study Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 Cost-effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: adaptation of INNOVATE and ETOPA data to the Netherlands Source: Annual Congress 2007 - Cost-effectiveness in diagnosis, therapy and care Year: 2007 Omalizumab (Xolair®) reduces exacerbations in adolescents more than in adults with allergic (IgE-mediated) asthma: a subgroup analysis of pooled clinical trials Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008 Th2 related biomarkers as predictors of airway eosinophilia in optimally treated smoking asthmatics: An observational study. Source: International Congress 2017 – Techniques in biomarker selection Year: 2017 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Phase 2, mutlicenter, double-blind study of CNTO 148, a human monoclonal anti-TNF α antibody, in symptomatic patients with severe persistent asthma Source: Annual Congress 2007 - Clinical trial: new biological approaches to respiratory diseases Year: 2007 Efficacy of Omalizumab in adult and pediatric severe allergic asthma according to presence of multiple allergic comorbidities: evidence from the STELLAIR study. Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma Source: International Congress 2015 – Immune aspects of asthma and other airway diseases Year: 2015 A single-center observational study assessing response to mepolizumab in severe eosinophilic asthma Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Effect of subcutaneous allergen immunotherapy on the natural course of allergic diseases: a retrospective cohort study Source: International Congress 2019 – Asthma education: lifestyle and adolescence Year: 2019 A randomized controlled study of omalizumab in children with moderate-to-severe persistent allergic asthma Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008